Table 3.

Summary of evidence for tandem autologous versus autologous-allogeneic hematopoietic cell transplantation in patients with multiple myeloma

Quality assessment			No of patients		Effect
No of studies	Design	Risk of bias	Auto-allo HCT	Auto-auto HCT	Relative (95% CI)	Absolute
Overall response rate
3	Biologically randomized trials	very serious1,2	248/275 (90.2%)	204/223 (91.5%)	RR 0.98 (0.92 to 1.05)	18 fewer per 1000 (from 73 fewer to 46 more)
Complete response
5	Biologically randomized trials	very serious1,2	257/456 (56.4%)	254/674 (37.7%)	RR 1.65 (1.25 to 2.19)	245 more per 1000 (from 94 more to 448 more)
At least very good partial response
1	Biologically randomized trials	very serious1,2	113/156 (72.4%)	272/366 (74.3%)	RR 0.97 (0.87 to 1.09)	22 fewer per 1000 (from 97 fewer to 67 more)
Event-free survival (ITT)
3	Biologically randomized trials	serious1	414	815	HR 0.83 (0.60 to 1.15)	-
Event-free survival (per-protocol)
4	Biologically randomized trials	very serious1,2	174	235	HR 0.78 (0.58 to 1.05)	-
Overall survival (ITT)
3	Biologically randomized trials	serious1	414	815	HR 0.80 (0.48 to 1.32)	-
Overall survival (per-protocol)
2	Biologically randomized trials	very serious1,2	83	131	HR 0.88 (0.33 to 2.35)	-
Non-relapse mortality
4	Biologically randomized trials	serious1	50/363 (13.8%)	25/684 (3.7%)	RR 3.55 (2.17 to 5.80)	93 more per 1000 (from 43 more to 175 more)
Grade II-IV GVHD3
4	Biologically randomized trials	serious1	126/485 (26%)	-	Proportion 28.26 (20.65 to 36.55)	-
Chronic GVHD3
4	Biologically randomized trials	serious1	206/356 (57.9%)	-	Proportion 60.69 (50.65 to 70.29)	-

1 Selective outcome reporting; 2 Per-protocol reporting of benefits; 3 GVHD: graft-versus-host disease.